Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Saturday, October 16, 2010
New Drug Reverses Scarring in Hepatitis B
FibroGen Inc. started a mid-stage study of a treatment aimed at reversing scarring of the liver from the hepatitis B virus.
The San Francisco biotech company said the study of its human monoclonal antibody, FT-3019, will be conducted in Hong Kong, where about 10 percent of the population has chronic hepatitis B.